University at Buffalo Opens FOXG1 Research Center to Advance Gene Therapy for Rare Disorder
核心洞察
The University at Buffalo (UB) has inaugurated the FOXG1 Research Center (搜索) (FRC) to focus on developing treatments for FOXG1 syndrome (搜索) and related neurodevelopmental disorders (搜索).
Researchers at the FRC are developing a viral gene therapy (搜索) showing promise in preclinical studies, with potential human clinical trials planned for as early as spring 2026.
The center is supported by the FOXG1 Research Foundation, which has raised over $7 million to advance research and clinical trials for FOXG1 syndrome (搜索).
The University at Buffalo (UB) has officially opened the FOXG1 Research Center (搜索) (FRC), marking a significant step forward in the pursuit of a cure for FOXG1 syndrome (搜索) and other related neurodevelopmental disorders (搜索). The center's launch was celebrated with a ribbon-cutting ceremony and a science symposium.
Focus on Viral Gene Therapy
At the heart of the FRC's mission is the development of a viral gene therapy (搜索) targeting the FOXG1 gene (搜索). Preclinical studies involving postnatal injections of the therapy in day-old mice have shown promising results, rescuing abnormalities in brain regions responsible for language, memory, and social interaction. The researchers aim to initiate human clinical trials as early as spring 2026, pending FDA approval.
Leadership and Personal Connection
The center is spearheaded by Soo-Kyung Lee, Empire Innovation Professor and Om P. Bahl Endowed Professor in the Department of Biological Sciences, and her husband, Jae Lee, professor of biological sciences. Their dedication stems from a personal connection: their daughter, Yuna, is one of approximately 1,000 individuals worldwide diagnosed with FOXG1 syndrome (搜索). This rare disorder results from a mutation in the FOXG1 gene (搜索), crucial for early brain development, leading to cognitive and physical disabilities and life-threatening seizures.
Collaborative Support and Funding
The FOXG1 Research Center (搜索) receives support from the FOXG1 Research Foundation. The foundation has raised over $7 million towards human clinical trials. The FRC is also exploring the use of artificial intelligence to assist children with speech and language disorders, further broadening its impact on neurodevelopmental conditions.
Future Directions
The center's establishment signifies a major advancement in translational research, with the goal of bringing innovative treatments from the laboratory to patients and families affected by FOXG1 syndrome (搜索). The convergence of gene therapy, AI, and dedicated research efforts offers renewed hope for addressing this rare and challenging disorder.